Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28065

1.

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.

Te Brake LHM, Boeree MJ, Aarnoutse RE.

Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201811-2101LE. [Epub ahead of print] No abstract available.

PMID:
30645149
2.

Reply to: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.

Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD.

Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201812-2281LE. [Epub ahead of print] No abstract available.

PMID:
30645140
3.

In vitro activity of colistin in combination with various antimicrobials against Acinetobacter baumannii species, a report from South Iran.

Kheshti R, Pourabbas B, Mosayebi M, Vazin A.

Infect Drug Resist. 2018 Dec 31;12:129-135. doi: 10.2147/IDR.S182585. eCollection 2019.

PMID:
30643441
4.

Dose-dependent Synergistic Interactions of Colistin with Rifampicin, Meropenem and Tigecycline against Carbapenem-resistant Klebsiella pneumoniae Biofilms.

Geladari A, Simitsopoulou M, Antachopoulos C, Roilides E.

Antimicrob Agents Chemother. 2019 Jan 14. pii: AAC.02357-18. doi: 10.1128/AAC.02357-18. [Epub ahead of print]

PMID:
30642942
5.

Towards better management of latent tuberculosis infection in children and young adults in the Maghreb. Conclusions of an expert meeting, Paris, 16 March 2018.

Delacourt C, Zellweger JP; Maghreb pediatric TB expert group.

Arch Pediatr. 2019 Jan 11. pii: S0929-693X(18)30261-6. doi: 10.1016/j.arcped.2018.12.001. [Epub ahead of print] No abstract available.

PMID:
30642745
6.

E-DNA detection of rpoB gene resistance in Mycobacterium tuberculosis in real samples using Fe3O4/polypyrrole nanocomposite.

Haddaoui M, Sola C, Raouafi N, Korri-Youssoufi H.

Biosens Bioelectron. 2018 Dec 7;128:76-82. doi: 10.1016/j.bios.2018.11.045. [Epub ahead of print]

PMID:
30640123
7.

Isoniazid-Resistant Rifampicin-Susceptible Tuberculosis in Children.

Morales Pérez C, Gomez-Pastrana D, Aragón Fernández C, Pérez Escolano E.

Arch Bronconeumol. 2019 Jan 8. pii: S0300-2896(18)30412-5. doi: 10.1016/j.arbres.2018.10.014. [Epub ahead of print] English, Spanish. No abstract available.

8.

Depicting the DNA binding and photo-nuclease ability of anti-mycobacterial drug rifampicin: A biophysical and molecular docking perspective.

Chakraborty A, Panda AK, Ghosh R, Roy I, Biswas A.

Int J Biol Macromol. 2019 Jan 8. pii: S0141-8130(18)34829-3. doi: 10.1016/j.ijbiomac.2019.01.034. [Epub ahead of print]

PMID:
30633932
9.

[Increase of antituberculosis efficiency of rifampicin embedded into phospholipid nanoparticles with sodium oleate].

Sanzhakov MA, Ipatova OM, Torkhovskaya TI, Tikhonova EG, Medvedeva NV, Zakharova TS, Prozorovskiy VN.

Biomed Khim. 2018 Nov;64(6):505-510. doi: 10.18097/PBMC20186406505. Russian.

PMID:
30632978
10.

Structural characterization and applications of a novel polysaccharide produced by Azospirillum lipoferum MTCC 2306.

Kumari P, Bhave M, Doble M.

World J Microbiol Biotechnol. 2019 Jan 10;35(1):17. doi: 10.1007/s11274-019-2588-y.

PMID:
30631968
11.

Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible.

Pena MJ, Chueca N, D'Avolio A, Zarzalejos JM, Garcia F.

Open Forum Infect Dis. 2018 Dec 10;6(1):ofy332. doi: 10.1093/ofid/ofy332. eCollection 2019 Jan.

12.

Evaluation of GeneXpert MTB/RIF Assay for Detection of Pulmonary Tuberculosis on Sputum Samples.

Yasemin A, Ahmad S, Afzal S, Ullah A, Sheed A.

J Coll Physicians Surg Pak. 2019 Jan;29(1):66-69. doi: 10.29271/jcpsp.2019.01.66.

PMID:
30630573
13.

Direct Drug Susceptibility Testing of Mycobacterium tuberculosis using the proportional method: a Multicenter Study.

Amini S, Hoffner S, Allahyar Torkaman M, Hamzehloo G, Nasiri MJ, Salehi M, Kashkooli GS, Shahraki M, Mohsenpoor M, Soleimanpour S, Mir R.

J Glob Antimicrob Resist. 2019 Jan 7. pii: S2213-7165(19)30004-9. doi: 10.1016/j.jgar.2018.12.022. [Epub ahead of print]

PMID:
30630107
14.

Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: an observational study to assess prevalence and causes.

Schneller-Pavelescu L, Caso EV, Martorell A, Romaní J, Lázaro M, Vilarrasa E, Díaz-Ley B, Vázquez-Osorio I, Palacios JS, Azaña JM, González-López MA, Cañueto J, Molina-Leyva A, Leiva-Salinas M, Navarro-Triviño FJ, Sánchez-Payá J, Pascual JC.

J Am Acad Dermatol. 2019 Jan 7. pii: S0190-9622(19)30005-2. doi: 10.1016/j.jaad.2018.12.043. [Epub ahead of print] No abstract available.

PMID:
30630028
15.

In vitro antimicrobial activity against equine Lawsonia intracellularis strains.

Pereira CER, Resende TP, Vasquez E, Lund LM, Guedes RMC, Gebhart CJ.

Equine Vet J. 2019 Jan 10. doi: 10.1111/evj.13071. [Epub ahead of print]

PMID:
30629755
16.

[One year of infectious diseases in review].

Clerc O.

Rev Med Suisse. 2019 Jan 9;15(N° 632-633):62-64. French.

PMID:
30629372
17.

Promising Chitosan-Coated Alginate-Tween 80 Nanoparticles as Rifampicin Coadministered Ascorbic Acid Delivery Carrier Against Mycobacterium tuberculosis.

Scolari IR, Páez PL, Sánchez-Borzone ME, Granero GE.

AAPS PharmSciTech. 2019 Jan 9;20(2):67. doi: 10.1208/s12249-018-1278-7.

PMID:
30627867
18.

Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin Induced CYP3A4 and MDR1 Gene Expression.

Abbott KL, Chaudhury CS, Chandran A, Vishveshwara S, Dvorak Z, Jiskrova E, Poulikova K, Vyhlidalova B, Mani S, Pondugula SR.

Mol Pharmacol. 2019 Jan 8. pii: mol.118.114587. doi: 10.1124/mol.118.114587. [Epub ahead of print]

19.

Genetic Determinants and Prediction of Antibiotic Resistance Phenotypes in Helicobacter pylori.

Lauener FN, Imkamp F, Lehours P, Buissonnière A, Benejat L, Zbinden R, Keller PM, Wagner K.

J Clin Med. 2019 Jan 7;8(1). pii: E53. doi: 10.3390/jcm8010053.

20.

Resistance of Mycobacterium tuberculosis strains to Rifampicin: A systematic review and meta-analysis.

Feyisa SG, Abdurahman AA, Jimma W, Chaka EE, Kardan-Yamchi J, Kazemian H.

Heliyon. 2019 Jan 1;5(1):e01081. doi: 10.1016/j.heliyon.2018.e01081. eCollection 2019 Jan.

Supplemental Content

Loading ...
Support Center